Now that Atara Biotherapeutics Inc’s volume has hit 1.72 million, investors get a glimpse of its size.

On Monday, Atara Biotherapeutics Inc (NASDAQ: ATRA) opened lower -4.15% from the last session, before settling in for the closing price of $0.71. Price fluctuations for ATRA have ranged from $0.20 to $3.08 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

A company in the Healthcare sector has jumped its sales by 25.21% annually for the last half of the decade. Company’s average yearly earnings per share was noted 79.08% at the time writing. With a float of $110.12 million, this company’s outstanding shares have now reached $119.36 million.

In an organization with 225 employees, it is important to assess its efficiency.

Atara Biotherapeutics Inc (ATRA) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Atara Biotherapeutics Inc is 7.74%, while institutional ownership is 60.74%. The most recent insider transaction that took place on Mar 04 ’24, was worth 17,888. In this transaction President and CEO of this company sold 24,844 shares at a rate of $0.72, taking the stock ownership to the 1,910,652 shares. Before that another transaction happened on Mar 04 ’24, when Company’s EVP, Chief Sci. & Tech Officer sold 10,746 for $0.72, making the entire transaction worth $7,737. This insider now owns 941,397 shares in total.

Atara Biotherapeutics Inc (ATRA) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.68 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 79.08% per share during the next fiscal year.

Atara Biotherapeutics Inc (NASDAQ: ATRA) Trading Performance Indicators

Check out the current performance indicators for Atara Biotherapeutics Inc (ATRA). In the past quarter, the stock posted a quick ratio of 0.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.45.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.61, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.40 in one year’s time.

Technical Analysis of Atara Biotherapeutics Inc (ATRA)

Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was inferior than the volume of 2.86 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 18.48%. Additionally, its Average True Range was 0.07.

During the past 100 days, Atara Biotherapeutics Inc’s (ATRA) raw stochastic average was set at 21.46%, which indicates a significant decrease from 27.78% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.95% in the past 14 days, which was lower than the 135.79% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $0.7612, while its 200-day Moving Average is $1.1277. However, in the short run, Atara Biotherapeutics Inc’s stock first resistance to watch stands at $0.7091. Second resistance stands at $0.7395. The third major resistance level sits at $0.7691. If the price goes on to break the first support level at $0.6491, it is likely to go to the next support level at $0.6195. Assuming the price breaks the second support level, the third support level stands at $0.5891.

Atara Biotherapeutics Inc (NASDAQ: ATRA) Key Stats

There are currently 119,359K shares outstanding in the company with a market cap of 81.00 million. Presently, the company’s annual sales total 8,570 K according to its annual income of -276,130 K. Last quarter, the company’s sales amounted to 4,250 K and its income totaled -60,450 K.